An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.
- DOI
- 10.1038/s41417-023-00712-0
- Published
- 2024 Mar
- Container
- Cancer gene therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41417-023-00712-0,
title = {An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.},
author = {Wang Q and Wei R and Guo S and Min C and Zhong X and Huang H and Cheng Z},
year = {2024},
journal = {Cancer gene therapy},
doi = {10.1038/s41417-023-00712-0},
url = {https://doi.org/10.1038/s41417-023-00712-0}
}RIS
TY - JOUR TI - An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. AU - Wang Q AU - Wei R AU - Guo S AU - Min C AU - Zhong X AU - Huang H AU - Cheng Z PY - 2024 JO - Cancer gene therapy DO - 10.1038/s41417-023-00712-0 UR - https://doi.org/10.1038/s41417-023-00712-0 ER -
APA
Q, W., R, W., S, G., C, M., X, Z., H, H., & Z, C. (2024). An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.. Cancer gene therapy. https://doi.org/10.1038/s41417-023-00712-0
Source records
- pubmed · retrieved 2026-09-27T11:28:17.595Z